HC Wainwright Has Bullish Forecast for SMMT FY2026 Earnings

Summit Therapeutics PLC (NASDAQ:SMMT) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for Summit Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.04) for the year, up from their previous forecast of ($1.06). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Summit Therapeutics’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Summit Therapeutics’ Q4 2026 earnings at ($0.26) EPS, Q1 2027 earnings at ($0.24) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($0.98) EPS.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Stifel Nicolaus decreased their price objective on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, July 24th. UBS Group reaffirmed a “neutral” rating on shares of Summit Therapeutics in a research report on Wednesday, September 23rd. Guggenheim reiterated a “buy” rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. Finally, The Goldman Sachs Group set a $41.00 target price on shares of Summit Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.61.

Summit Therapeutics Stock Performance

Summit Therapeutics stock opened at $17.83 on Monday. The business has a fifty day moving average of $16.41 and a two-hundred day moving average of $16.15. Summit Therapeutics has a twelve month low of $12.07 and a twelve month high of $29.23.

Institutional Investors Weigh In On Summit Therapeutics

Institutional investors have recently bought and sold shares of the company. IFP Advisors Inc grew its holdings in Summit Therapeutics by 792.3% in the third quarter. IFP Advisors Inc now owns 1,508 shares of the company’s stock worth $26,000 after purchasing an additional 1,339 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in shares of Summit Therapeutics during the 3rd quarter valued at $30,000. CX Institutional lifted its holdings in shares of Summit Therapeutics by 244.8% during the 3rd quarter. CX Institutional now owns 2,038 shares of the company’s stock valued at $34,000 after purchasing an additional 1,447 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Summit Therapeutics during the 3rd quarter valued at $34,000. Finally, Global Retirement Partners LLC lifted its holdings in shares of Summit Therapeutics by 200.0% during the 3rd quarter. Global Retirement Partners LLC now owns 2,058 shares of the company’s stock valued at $35,000 after purchasing an additional 1,372 shares during the last quarter. 4.61% of the stock is currently owned by institutional investors and hedge funds.

About Summit Therapeutics

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.